Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs ServiceNow Inc (NOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs ServiceNow Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $287 (market cap $39.89B), while ServiceNow Inc trades at $112.34 (market cap $111.08B). The key difference: ServiceNow Inc is far larger — about 2.8× Alnylam Pharmaceuticals, Inc.'s market cap, and ServiceNow Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | NOW | |
|---|---|---|
Market Cap | $39.89B | $111.08B |
Sector | Health | Technology |
52-Week High | $491.22 | $199.24 |
52-Week Low | $278.09 | $83.00 |
Enterprise Value | $38.15B | $108.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
ServiceNow (NOW) trades at $107.71, down 1.04% on the day, with a strong bullish technical signal from moving averages. The company demonstrates robust fundamentals with revenue growing from $7.2B in 2022 to $13.3B in 2025 and a consistent net income margin around 13%. Recent news highlights the company's positioning as an 'AI control tower' and its active participation in major technology conferences.
The outlook is positive with 86% analyst buy ratings and a $138.39 consensus price target, implying ~28% upside. Key opportunities include AI-driven growth and strong cash flow generation, while risks involve high valuation multiples (P/E 64.11) and execution in a competitive enterprise software market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About ServiceNow Inc
ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management (ITSM), expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service (PaaS).
Read more on NOW →
